Report Highlights

India Tachycardia Market: Market Overview

The tachycardia market in India encompasses diagnostics, pharmacological therapies, electrophysiology procedures, and implantable cardiac devices used to manage supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, and related arrhythmias. Valued at USD 412 million in 2024, the market is structurally shaped by a dual-track healthcare system: a heavily government-influenced public sector funded by national health programmes and a high-volume private hospital sector led by chains such as Apollo Hospitals, Fortis Healthcare, and Narayana Health. Policy has been the dominant force in expanding diagnostic reach and making device-based therapies accessible beyond the top eight metropolitan centres.

Private sector innovation has led in procedural technology adoption, particularly radiofrequency catheter ablation and cryo-ablation, primarily concentrated in Mumbai, Delhi, Chennai, and Bengaluru. The public sector, by contrast, has driven volume through subsidised drug access and procedure coverage under national insurance programmes. The asymmetry between diagnostic capacity and treatment infrastructure remains the market's most significant structural tension, with an estimated 4.2 million Indians living with undiagnosed or undertreated arrhythmias, according to projections from the Indian Heart Rhythm Society.

Policy-Driven Growth in Tachycardia Care

Three specific policy mechanisms are materially expanding the tachycardia market. First, the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY), administered by the National Health Authority, covers cardiac electrophysiology procedures including catheter ablation under Health Benefit Package codes, with reimbursement rates revised upward in 2023 to INR 45,000–85,000 per procedure depending on complexity. This directly expanded the paying patient pool for ablation procedures to include approximately 500 million beneficiaries previously excluded from private cardiac care, generating measurable volume increases at empanelled hospitals.

Second, the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), under the Ministry of Health and Family Welfare, mandates cardiac screening at Community Health Centres and Health and Wellness Centres, creating a structured referral pathway for arrhythmia detection at the primary care level. Third, the Medical Devices Rules 2017, enforced by the Central Drugs Standard Control Organisation (CDSCO), introduced a mandatory device registration pathway that has simultaneously quality-filtered the market and incentivised global manufacturers to localise regulatory submissions, accelerating approved product availability for Indian cardiologists by an average of fourteen months compared to pre-2017 timelines.

Regulatory Barriers and Compliance Costs

The CDSCO's Class C and Class D device classification framework, established under Schedule V of the Medical Devices Rules 2017, subjects implantable cardiac devices including ICDs and cardiac resynchronisation therapy devices to mandatory clinical performance data requirements that often necessitate India-specific bridging studies. Average CDSCO approval timelines for Class D cardiac implantables run to eighteen to twenty-four months from submission, compared to nine to twelve months under the US FDA 510(k) pathway. This delay costs manufacturers an estimated USD 1.5–2.5 million per product in delayed revenue and extended compliance operational costs before a single unit reaches a hospital.

Local content and import duty structures present additional barriers. The Union Budget 2023–24 maintained a 12% basic customs duty on cardiac stents and related electrophysiology consumables imported under Chapter 90 of the Customs Tariff Act, 1975. The Bureau of Indian Standards (BIS) has been empanelled to enforce quality certification for select medical devices under the Medical Devices (Quality Management System) Regulations, adding a parallel certification requirement that smaller distributors frequently fail to meet within required timelines, effectively concentrating market access among well-resourced multinationals and large domestic distributors.

Policy-Created Opportunities in India

The Production Linked Incentive (PLI) Scheme for Medical Devices, notified under the Department of Pharmaceuticals with a total outlay of INR 3,420 crore across four tranches, explicitly covers cardiac electrophysiology devices in its eligible product categories. Manufacturers who establish domestic production or value-addition facilities qualifying under PLI receive financial incentives of 5% on incremental sales for five consecutive years. This creates a direct cost-competitiveness advantage for companies willing to establish manufacturing in the designated medical device parks in Andhra Pradesh, Telangana, Tamil Nadu, and Himachal Pradesh, where state governments provide additional land and infrastructure subsidies.

The Ayushman Bharat Digital Mission (ABDM), under the National Health Authority, is building a federated electronic health records infrastructure that will generate longitudinal cardiac monitoring data at national scale for the first time. This infrastructure creates a policy-backed opportunity for remote cardiac monitoring device manufacturers and AI-based arrhythmia detection software developers, a segment currently underserved in India. CDSCO's 2023 draft guidance on Software as a Medical Device (SaMD) provides a defined regulatory pathway for AI-ECG tachycardia detection tools, unlocking a segment that previously operated in a regulatory grey zone and deterred serious investment.

Market at a Glance

Leading Market Participants

• Medtronic India
• Abbott India
• Boston Scientific India
• Biosense Webster (Johnson & Johnson MedTech)
• Philips India
• GE HealthCare India
• Siemens Healthineers India
• Zydus Lifesciences
• Sun Pharmaceutical Industries
• Schiller Healthcare India

Regulatory and Policy Environment

The primary legislative framework governing the tachycardia device and drug market in India is the Medical Devices Rules 2017, issued under the Drugs and Cosmetics Act 1940, with the CDSCO under the Ministry of Health and Family Welfare as the administering authority. All implantable cardiac devices—including ICDs, cardiac loop recorders, and electrophysiology catheters—are classified as Class C or Class D and require a CDSCO licence under Form MD-14 before import or manufacture. The Drug Price Control Order 2013, administered by the National Pharmaceutical Pricing Authority (NPPA), caps prices of essential cardiac drugs including amiodarone, adenosine, and metoprolol, constraining pharmaceutical margins but ensuring affordability at the public hospital level. India's framework is more restrictive than Singapore's HSA pathway or Australia's TGA framework in terms of local clinical data requirements, though it is broadly aligned with the ASEAN Medical Device Directive in classification structure.

Upcoming regulatory changes expected by 2026 include mandatory unique device identification (UDI) labelling for Class C and D cardiac devices, as proposed in the CDSCO's draft amendment to Medical Devices Rules 2017 circulated in September 2023. This will require manufacturers to register all cardiac implantables in the SUGAM online portal with device-level traceability data—a compliance investment estimated at USD 200,000–500,000 per manufacturer for system integration. Additionally, the NPPA has signalled a review of cardiac device price benchmarking under the Essential Commodities Act 1955, which, if extended to electrophysiology catheters and ablation systems, would materially compress per-procedure revenues for hospitals and device importers operating on current margin structures.

Long-Term Policy Outlook for India's Tachycardia Market

By 2032, India's tachycardia policy environment is expected to shift meaningfully toward outcome-based reimbursement structures under an evolved PMJAY framework. The National Health Authority has publicly committed to piloting Diagnosis-Related Group (DRG)-based pricing for cardiac procedures by 2027, which will replace the current fixed Health Benefit Package rates. This transition incentivises procedural efficiency and post-procedure monitoring, creating structural demand for integrated care pathways that combine electrophysiology procedures with remote cardiac monitoring—a segment where domestic manufacturers under the PLI scheme are positioned to capture share from incumbents.

The Indian government's broader target to achieve universal health coverage by 2030, embedded in the National Health Policy 2017 and reinforced through successive Union Budget commitments, will require substantial expansion of cardiac care infrastructure at district hospital level. The Ministry of Health's Strengthening of Tertiary Care Cancer Facilities scheme provides a precedent for technology-linked capital grants that is likely to be replicated for cardiac centres. If the proposed National Cardiac Care Mission—discussed in health ministry working groups since 2022—is formally notified by 2026, it will directly fund electrophysiology lab establishment at fifty district hospitals across twelve states, creating a sustained procurement pipeline for catheter ablation systems, ECG equipment, and antiarrhythmic drug supply chains through 2032.